CVS Health insider trading
Every open-market purchase and sale by CVS Health's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following CVS Health’s insiders pay?
From January 6, 2010 to May 21, 2026, 29 insiders reported 26 open-market purchases and 33 sales not made under a pre-set plan in CVS Health. Twelve months after each purchase was reported, the shares were +3.4% against the S&P 500 on average (median +9.3%), over 26 purchases with a full year of prices; 69% beat the index. After sales, the shares moved 0.0% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on January 7, 2010 into $28,278 by November 2, 2026, +6.4% a year. It held shares 64% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $32,981 (+7.4% a year), and held throughout $88,989 (+13.9%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Ludwig Edward J | Director | 7 | +6.4% (7) | 71% | 0 | — | May 2, 2024 |
| Foulkes Helena | EVP & President-CVS Pharmacy | 0 | — | — | 5 | −6.9% (5) | February 21, 2018 |
| Lofberg Per Gh | EVP and President, Caremark | 5 | −3.0% (5) | 60% | 0 | — | February 15, 2012 |
| Bisaccia Lisa | SVP, Chief HR Officer | 0 | — | — | 3 | +20.0% (3) | February 23, 2012 |
| Clark James David | SVP, Cont & Chief Acct Officer | 0 | — | — | 3 | −10.9% (3) | March 7, 2025 |
| Mcguigan Stuart M | SVP and CIO | 0 | — | — | 3 | +8.1% (3) | March 20, 2012 |
| Aguirre Fernando | Director | 2 | +12.9% (2) | 100% | 0 | — | March 11, 2019 |
| Brennan Troyen A | EVP and Chief Medical Officer | 0 | — | — | 2 | +15.2% (2) | November 3, 2021 |
| Brown C David II | Director | 2 | +0.3% (2) | 50% | 0 | — | March 11, 2019 |
| Dorman David W | Director | 2 | +0.3% (2) | 50% | 0 | — | March 11, 2019 |
| Mahoney Michael F | Director | 2 | +11.8% (2) | 100% | 0 | — | February 19, 2025 |
| Millon Jean Pierre | Director | 0 | — | — | 2 | +6.5% (2) | August 22, 2012 |
| Murray Terrence | Director | 1 | +18.2% (1) | 100% | 1 | +18.2% (1) | May 25, 2011 |
| Robbins Larry | Director | 0 | — | — | 2 | +7.6% (1) | May 21, 2026 |
| Roberts Jonathan C | EVP & President, CVS/caremark | 0 | — | — | 2 | −6.4% (2) | February 11, 2016 |
| Shah Prem S | EVP and Pres-Pharm, Consumer W | 0 | — | — | 2 | −27.1% (2) | February 16, 2024 |
| Banks Edwin M | Director | 0 | — | — | 1 | +10.9% (1) | March 16, 2012 |
| Denton David M | EVP and CFO | 0 | — | — | 1 | −16.2% (1) | November 30, 2018 |
| Finley Sara | SVP, Gen Counsel | 0 | — | — | 1 | −23.7% (1) | March 3, 2010 |
| Finucane Anne A. | Director | 0 | — | — | 1 | +14.6% (1) | August 29, 2025 |
| Gold Stephen J | SVP & CIO | 1 | +3.1% (1) | 100% | 0 | — | July 10, 2012 |
| Lotvin Alan | EVP and President-CVS Caremark | 1 | −9.2% (1) | 0% | 0 | — | May 13, 2020 |
| Lynch Karen S | President and CEO | 1 | −45.5% (1) | 0% | 0 | — | May 5, 2023 |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer | 0 | — | — | 1 | — | May 11, 2026 |
| Moriarty Thomas M | EVP & General Counsel | 1 | +2.8% (1) | 100% | 0 | — | October 3, 2012 |
| Piccolo C A | Director | 0 | — | — | 1 | +16.2% (1) | December 17, 2012 |
| Sansone Guy P | Director | 1 | +38.4% (1) | 100% | 0 | — | June 9, 2025 |
| Swift Richard J | Director | 0 | — | — | 1 | −22.5% (1) | August 18, 2017 |
| Williams Kristen Gibney | Director | 0 | — | — | 1 | +2.4% (1) | September 7, 2011 |
When several insiders traded CVS Health
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of CVS Health in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged +8.5% against the index. After 2 selling crowds, +3.3%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| May 31, 2024 | 2 buying | −10.1% | −12.3% | −2.8% |
| March 29, 2019 | 4 buying | −2.2% | +11.7% | +19.8% |
| May 31, 2018 | 2 buying | +10.3% | +26.2% | −16.4% |
| February 29, 2012 | 3 selling | +4.3% | −2.9% | +2.7% |
| November 30, 2011 | 3 selling | +5.8% | +9.5% | +5.3% |